526-21-6

Basic information

• Product Name: Glycine,N-(2-aminobenzoyl)-
• Synonyms: 2-Aminohippuric acid
• CAS NO: 526-21-6
• Molecular Formula: C₉H₁₀N₂O₃
• Molecular Weight: 194.1873
• Mol File: 526-21-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 498.1 °C at 760 mmHg
• Flash Point: 255.1 °C
• Appearance: /
• Density: 1.356 g/cm³
• Vapor Pressure: 9.65E-11mmHg at 25°C
• Refractive Index: 1.62
• CAS DataBase Reference: Glycine,N-(2-aminobenzoyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Glycine,N-(2-aminobenzoyl)-(526-21-6)
• EPA Substance Registry System: Glycine,N-(2-aminobenzoyl)-(526-21-6)

Safety Data

• Hazardous Substances Data: 526-21-6(Hazardous Substances Data)

Usage

General Description

Glycine,N-(2-aminobenzoyl)-, also known as N-(2-Boc-amino)-5-benzyloxyglycine, is a chemical compound that falls under the category of amino acids. It is a derivative of glycine with a benzoyl group attached to the nitrogen atom. Glycine,N-(2-aminobenzoyl)- is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It is also used as a reagent in organic synthesis and as a precursor in the production of peptide-based drugs. Additionally, it has been studied for its potential role in the treatment of neurological disorders and as a building block for the development of new materials and bioconjugates.

InChI:InChI=1/C9H10N2O3/c10-7-4-2-1-3-6(7)9(14)11-5-8(12)13/h1-4H,5,10H2,(H,11,14)(H,12,13)

Upstream product

• 10167-23-4 N-(2-nitrobenzoyl)glycine 
• 118-48-9 isatoic anhydride 
• 56-40-6 glycine 
• 118-92-3 anthranilic acid 
• 610-14-0 2-nitrobenzyl chloride 
• 552-16-9 ortho-nitrobenzoic acid 
• 63254-88-6 2-{[(benzyloxy)carbonyl]amino}benzoic acid 
• 866431-50-7 methyl [(2-{[(benzyloxy)carbonyl]amino}benzoyl)amino]acetate 
• 150374-96-2 N-(2-nitrobenzoyl)glycine benzyl ester 
• 21563-73-5 2-aminobenzoyl chloride 
• 67482-93-3 o-aminobenzoylglycyl-p-nitro-L-phenylalanyl-L-proline 
• 5973-34-2 (2-aminobenzoylamino)acetic acid ethyl ester 
• 5177-49-1 ethyl 2-(2-nitrobenzamido)acetate 

Downstream Products

• 105217-20-7 2-Ureido-hippursaeure 
• 67482-93-3 o-aminobenzoylglycyl-p-nitro-L-phenylalanyl-L-proline 
• 97609-01-3 2-(4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)acetic acid 
• 127373-66-4 N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glycine 
• 86-96-4 1,2,3,4-tetrahydro-quinazoline-2,4-dione 
• 14663-53-7 3-carboxymethyl-3,4-dihydro-4(1H)-quinazolinone 
• 866431-51-8 2-amino-N-{2-[(1-{[(methyl)(phenyl)amino]carbonyl}cyclopentyl)amino]-2-oxoethyl}benzamide 
• 58352-46-8 N-(N-acetyl-anthraniloyl)-glycine 

Relevant articles and documents

TARGETED DELIVERY TO BETA CELLS

The disclosure includes zinc prodrugs for targeted delivery of therapeutic, diagnostic or imaging agents to β-cells and methods of use therefor. The disclosure also includes targeted delivery of small molecules to β-cells that stabilize and activate CRISP

Application of the 'direct amide cyclization' to peptides containing an anthranilic acid residue

The 2,2-disubstituted 2H-azirin-3-amines 7a-7c were used as amino acid synthons to prepare linear peptides derived from anthranilic acid. These linear peptides, which contain α,α-disubstituted α-amino acids, were synthesized by using the 'azirine/oxazolon

Synthesis and in Vitro Aldolase Reductase Inhibitory Activity of Compounds Containing an N-Acylglycine Moiety

A number of N-benzoylglycines (6), N-acetyl-N-phenylglycines (7), N-benzoyl-N-phenylglycines (8), and tricyclic N-acetic acids (9-12) were synthesized as analogues of the N-acylglycine-containing aldolase reductase inhibitors alrestatin and 2-oxoquinoline-1-acetic acid.Derivatives of 6, which represent ring-simplified analogues of alrestatin, are very weak inhibitors of aldolase reductase obtained from rat lens, producing 50percent inhibition only at concentrations exceeding 100 μM.Compounds of series 7 were designed as ring-opened analogues of the 2-oxoquinolines.While this derivatives are more potent than compounds of series 6 (IC 50s of 6-80 μM), they are less active than the corresponding 2-oxoquinolines.Analogues of series 8 were designed as hybrid structures of both alrestatin and the 2-oxoquinoline-1-acetic acids.These compounds are substantially more potent than compounds of series 6 and 7 and display inhibitory activities comparable to or greater than alrestatin or the 2-oxoquinolines (IC 50s of 0.1-10 μM).Of the rigid analogues of 8, the most potent derivative is benzoxindol (12) with an IC 50 of 0.67 μM, suggesting that fusion of the two aromatic rings of 8 in a coplanar conformation may optimize affinity for aldose reductase in this series.